Prostate Progress, a UK research programme led by Prostate Cancer Research (PCR) in partnership with the NHS, is expanding ...
Alongside the CEO appointment, Gianluca Fuggetta joined as chief financial officer. Prior to joining Sibylla, Fuggetta served ...
The sticking point for Sanofi could be Insmed's sky-high valuation, with the report suggesting the pharma group would have to ...
Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the ...
Rasonque has been applauded as a major step forward in the treatment of pancreatic cancer, a notoriously aggressive and ...
MSD joins Johnson & Johnson, Novartis, and Eli Lilly among London-based Isomorphic's publicly announced R&D partners. While ...
Livsayis (cemdisiran) has been approved by the FDA for adults with AChR antibody-positive gMG, the most common form of the ...
Novartis has raised its peak sales expectations for three key growth products – Kesimpta, Scemblix, and Leqvio – by around $4 billion as it targets 5% annual revenue growth between 2026 and 2031.
Sanofi is already a big player in Gaucher disease, selling the ERT Cerezyme (imiglucerase) for all three types, as well as ...
In a new pharmaphorum podcast, Nicole Raleigh caught up with Jane Li, vice president and general manager for companion ...
Diabetes drug development has changed more in the last 10 years than in the previous three decades combined. Indeed, today, ...
The UK government has proposed changes to the definition of gene therapies and other genetic medicines, aiming to give ...